Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
List view / Grid view
Filter the results
11 May 2015 | By Victoria White
Cidara Therapeutics has announced that the FDA has designated the Company’s lead antifungal product candidate, CD101 IV, as a QIDP with Fast Track status...